Antidepressant-like activity of typical antidepressant drugs in the forced swim test and tail suspension test in mice is augmented by DMPX, an adenosine A_{2A} receptor antagonist by Poleszak, Ewa et al.
ORIGINAL ARTICLE
Antidepressant-Like Activity of Typical Antidepressant Drugs
in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented
by DMPX, an Adenosine A2A Receptor Antagonist
Ewa Poleszak1 & Aleksandra Szopa1 & Karolina Bogatko1 & Elżbieta Wyska2 & Sylwia Wośko1 & Katarzyna Świąder1 &
Urszula Doboszewska3 & Aleksandra Wlaź4 & Andrzej Wróbel5 & Piotr Wlaź3 & Anna Serefko1
Received: 26 July 2018 /Revised: 31 August 2018 /Accepted: 11 September 2018 /Published online: 28 September 2018
Abstract
Unsatisfactory therapeutic effects of currently used antidepressants force to search for new pharmacological treatment strategies.
Recent research points to the relationship between depressive disorders and the adenosinergic system. Therefore, the main goal of
our studies was to evaluate the effects of DMPX (3 mg/kg, i.p.), which possesses selectivity for adenosine A2A receptors
versus A1 receptors, on the activity of imipramine (15 mg/kg, i.p.), escitalopram (2.5 mg/kg, i.p.), and reboxetine (2 mg/kg,
i.p.) given in subtherapeutic doses. The studies carried out using the forced swim and tail suspension tests in mice showed that
DMPX at a dose of 6 and 12 mg/kg exerts antidepressant-like effect and does not affect the locomotor activity. Co-administration
of DMPX at a dose of 3 mg/kg with the studied antidepressant drugs caused the reduction of immobility time in both behavioral
tests. The observed effect was not associated with an increase in the locomotor activity. To evaluate whether the observed effects
were due to a pharmacokinetic/pharmacodynamic interaction, the levels of the antidepressants in blood and brain were measured
using high-performance liquid chromatography. It can be assumed that the interaction between DMPX and imipramine was
exclusively pharmacodynamic in nature, whereas an increased antidepressant activity of escitalopram and reboxetine was at least
partly related to its pharmacokinetic interaction with DMPX.
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Introduction
Adenosine is widely distributed throughout the central nervous
system (CNS). It functions as an endogenous agonist active at
purinoreceptors (Berk et al. 2001). Adenosine modulates neu-
ronal function via controlling the release of various neurotrans-
mitters (Sebastião and Ribeiro 2009), e.g., it highly inhibits
dopamine (DA), γ-aminobutyric acid (GABA), glutamate
(Glu), acetylcholine (ACh), serotonin (5-HT), and noradrena-
line (NA) release (Sebastião and Ribeiro 1996). The adenosine
receptors (ARs) belong to the G protein coupled receptor su-
perfamily (Fredholm et al. 2000; Olah and Stiles 2000). At least
four ARs subtypes are known: A1, A2A, A2B, and A3, which are
d istributed in different organ systems and control various phys-
iological functions in the human body (Olah and Stiles 1992,
2000; Fredholm et al. 2000, 2001). A1R and A2AR are mainly
located in the CNS (especially in the cortex and striatum, re-
spectively), whereas both A2BR and A3R are present in the
brain in low amount (Corset et al. 2000).
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Studies aimed at unraveling the neurobiological basis of
depression and the mechanisms underlying antidepressant ef-
fects of drugs emphasize the role of the adenosinergic system in
the regulation of mood (Cunha et al. 2008; Lara 2010; Gomes
et al. 2011). Because the adenosinergic system modulates neu-
rotransmission its impact on depressive behavior is complex
(Scaccianoce et al. 1989; Chau et al. 1999; Okada et al. 2001;
Yamato et al. 2002). Depressant-like effect of adenosine and its
analogues has been demonstrated in animal behavioral despair
tests (Minor et al. 1994; Hunter et al. 2003). Moreover, the
administration of classic antidepressants counteracted this effect
(Kulkarni and Mehta 1985). The results of preclinical investi-
gations highlight in particular the relationship between the ma-
nipulation of A2AR and depression and suggest that A2AR an-
tagonists may constitute a novel strategy for the treatment of
depressive disorders (Cunha 2008; Gomes et al. 2011). El
Yacoubi et al. (2001, 2003) demonstrated that A2AR knockout
mice are predisposed to the occurrence of antidepressant-like
behavior. Likewise, Cunha et al. (2006) observed that blockade
of these receptors inhibits changes in the hippocampus caused
by one of the major environmental factors conducive to depres-
sion, i.e., stress. Furthermore, the therapeutic strategies current-
ly used in depressed patients also affect the adenosinergic sys-
tem (e.g., desipramine, chlorimipramine, nortriptiline, tricyclic
antidepressant drugs (TCAs), are able to bind to the ARs)
(Deckert and Gleiter 1989).
Because of an increasing evidence that adenosine neurotrans-
mission is engaged in the development of psychiatric disorders,
including major depressive disorder (Kaster et al. 2015; Ortiz
et al. 2015; Ali-Sisto et al. 2016), and in the mechanisms under-
lying antidepressant effects (Deckert and Gleiter 1989;
Fredholm et al. 1999; Cunha et al. 2008; Lara 2010; Gomes
et al. 2011), while the number of prescribed drugs is growing
(Murray and Lopez 1997; Tondo et al. 2003; Hashimoto 2011),
the possible interaction between selective A2AR antagonist and
commonly used antidepressants should be examined. Therefore,
we assessed the antidepressant-like effect of DMPX, a synthetic
analog of caffeine, which possesses higher selectivity for A2A
receptors versus A1 receptors (Armentero et al. 2011), in two
widely used preclinical screening tests, the forced swim test
(FST) (Porsolt et al. 1977) and tail suspension test (TST)
(Steru et al. 1985). In the next step, we examined the effects of
DMPXon the antidepressant activity of a TCA, a selective 5-HT
reuptake inhibitor (SSRI), and a selective NA reuptake inhibitor
(SNRI), imipramine, escitalopram, and reboxetine, respectively.
To exclude false positive outcomes obtained in the FST and
TST, animal’s spontaneous locomotor activity was measured.
Further, to evaluate whether the observed effects during short-
term exposure to inescapable and uncontrollable stress were due
to a pharmacokinetic/pharmacodynamic interaction, the levels
of the studied antidepressants in the collected biological material
(blood and brain tissue) were measured using a high-
performance liquid chromatography (HPLC) method.
Materials and Methods
Animals
The experiment was carried out on 336 naïve adult male
albino Swiss mice weighing 25–30 g, purchased from the
licensed breeder (Kołacz, Warsaw, Poland). The animals
were housed in the environmentally controlled rooms (tem-
perature maintained at 21–25 °C and humidity 40–60%) in
standard cages in groups of 10 with unlimited access to
water and food. The rooms were illuminated with a 12-h
light/dark cycle. The procedures began after at least 1-week
acclimation period in the laboratory conditions and were
performed between 8 a.m. and 3 p.m. to minimize circadian
influences. Behavioral tests were video recorded and then
analyzed by two blind experimenters. All procedures were
conducted in accordance with the European Communities
Council Directive and Polish legislation acts concerning
animal experimentations. The procedures and protocols
were approved by the First Local Ethics Committee at the
Medical University of Lublin (license no. 5/2015).
Drug Administration
DMPX (3,7-dimethyl-1-propargylxanthine, 3, 6, and
12 mg/kg, Sigma-Aldrich, Poznań, Poland) was suspended
in a 1% aqueous solution of Tween 80 (POCH S.A.,
Gliwice, Poland). Imipramine hydrochloride (15 mg/kg,
Sigma-Aldrich), reboxetine mesylate (2.5 mg/kg, Ascent
Scientific, Cambridge, UK), and escitalopram oxylate
(2 mg/kg, Sigma-Aldrich) were dissolved in 0.9% NaCl. All
solutions of antidepressants were administered intraperitone-
ally (i.p.) 60min, whereas DMPX suspension was injected i.p.
30 min prior behavioral testing. The volume of all adminis-
tered solutions/suspension was 0.01ml/g. The doses and treat-
ment schedules were selected on the basis of literature and the
results of our previous experiments (Poleszak 2007; Poleszak
et al. 2005, 2011, 2013, 2016a,b; Szewczyk et al. 2002, 2009;
Szopa et al. 2016). Animals from the control groups received
i.p. injections of saline.
FST
FST was carried out according to the method of Porsolt et al.
(1977). Each mouse was placed individually for 6 min into a
glass cylinder (height 25 cm, diameter 10 cm) with 15 cm of
water at 23–25 °C. After the first 2 min of the test, total dura-
tion of immobility (in seconds) was measured. An animal was
judged to be immobile when it ceased struggling and
remained floating motionless and making only movements
allowing to keep the head just above the surface of water.
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TST
TST was carried out according to the method of Steru et al.
(1985). Each mouse was suspended for 6 min by the tail (2 cm
from the end of the tail) using adhesive tape. After the first
2 min of the test, total duration of immobility (in seconds) was
measured. An animal was judged to be immobile when it
ceased moving limbs and body, making only movements
allowing to breathe.
Spontaneous Locomotor Activity
Spontaneous locomotor activity was assessed using Opto-
Varimex-4 Auto-Track (Columbus Instruments, Columbus,
OH, USA). Plexiglas cages with lids (43 × 43 × 32 cm) were
equipped with a set of four infrared emitters and four detectors
monitoring mice movements. Each animal was placed individ-
ually for 6 min into a cage to measure the distance (in cm)
traveled between the second and the sixth minutes, which cor-
responds to the time interval analyzed in the FST and TST.
Determination of Antidepressant Levels in Serum
and Brain Homogenates
To acquire blood and brain for pharmacokinetic studies, mice
were decapitated in an appropriate time after injection of ex-
amined drugs with or without DMPX. The blood was collect-
ed into Eppendorf tubes and allowed to cloth. Then the sam-
ples were centrifuged for 10 min at 1000 rpm and the serum
was collected into polyethylene tubes and frozen at − 25 °C.
Brains, just after decapitation, were dissected from the skulls,
rinsed with 0.9% NaCl, and frozen at − 25 °C.
Brain and serum concentrations of antidepressants were
assayed by HPLC method as it was described previously
(Poleszak et al. 2016a; Szopa et al. 2016).
Calibration curves that were developed on the basis of the
ratio of the peak heights of the tested compounds to internal
standard versus the concentration of the drugwere linear in the
tested concentration ranges. No interfering peaks were ob-
served in the chromatograms. The assays were reproducible
with low intra- and interday variation (a coefficient of varia-
tion less than 10%). The extraction efficiencies of the analyzed
compounds and internal standards ranged from 66 to 97%.
Concentrations of antidepressants were expressed in ng/ml
of serum and ng/g of wet brain tissue.
Statistical Analysis
Statistical analysis was performed using one-way analysis of
variance (ANOVA) with Dunnett’s post hoc test, two-way
ANOVA with Bonferroni’s post hoc test, or Student’s t test,
depending on the study design. All results are presented as
mean ± SEM for each experimental group. P values < 0.05
were considered statistically significant.
Results
FST
DMPX Dose-Effect Relationship in FST
In dose-effect studies, DMPX was used in three different
doses: 3, 6, and 12 mg/kg (Fig. 1a). The statistical analysis
of the FST results showed that DMPX at doses of 6 and
12 mg/kg exhibited an antidepressant-like activity. DMPX at
a dose of 3 mg/kg had no statistically significant influence on
mice behavior in the FST (one-way ANOVA: F(3,36) =
13.48, *p < 0.05, ***p < 0.001, p > 0.05, respectively).
Effect of Combined Administration of DMPX and Tested
Antidepressants in FST
Effect of Combined Administration of DMPX and Imipramine
in FST DMPX (3 mg/kg) and imipramine (15 mg/kg), admin-
istered alone, did not affect the immobility in the FST
(p > 0.05) in mice. However, when given together, the dura-
tion of mouse immobility was significantly shortened
(p < 0.0001) (Fig. 2a).
Two-wayANOVA showed a significant effect of imipramine
(F(1,36) = 29.18, p < 0.001), a significant effect of DMPX
(F(1,36) = 32.23, p < 0.001), and a significant interaction be-
tween imipramine and DMPX (F(1,36) = 20.83, p < 0.001).
Effect of Combined Administration of DMPX and Escitalopram
in FST DMPX (3 mg/kg) and escitalopram (2 mg/kg), adminis-
tered alone, did not affect the immobility in the FST (p > 0.05)
in mice. However, when given together, the duration of mouse
immobility was significantly shortened (p < 0.001) (Fig. 2a).
Two-way ANOVA showed a significant effect of
escitalopram (F(1,35) = 23.20, p < 0.001), a significant effect
of DMPX (F(1,35) = 31.16, p < 0.001), and no interaction be-
tween escitalopram and DMPX (F(1,35) = 19.94, p < 0.001).
Effect of Combined Administration of DMPX and Reboxetine
in FST DMPX (3 mg/kg) and reboxetine (2.5 mg/kg), admin-
istered alone, did not affect the immobility in the FST
(p > 0.05) in mice. However, when given together, the dura-
tion of mouse immobility was significantly shortened
(p < 0.0001) (Fig. 2a).
Two-way ANOVA demonstrated a significant effect of
reboxetine (F(1,36) = 17.88, p = 0.0002), a significant effect
of DMPX (F(1,36) = 13.27, p = 0.0008), and a significant in-
teraction between reboxetine and DMPX (F(1,36) = 6.772,
p = 0.0134).
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TST
DMPX Dose-Effect Relationship in TST
In dose-effect studies, DMPX was used in three different
doses: 3, 6, and 12 mg/kg (Fig. 1b). The statistical analysis
of the TST results showed that DMPX at a dose of 6 and
12 mg/kg had an antidepressant-like activity, which was man-
ifested by the shortening of the duration of immobility. DMPX
at a dose of 3 mg/kg had no statistically significant influence
on mice behavior in the FST (one-way ANOVA: F(3,36) =
13.48, *p < 0.05, **p < 0.01, p > 0.05, respectively).
Effect of Combined Administration of DMPX and Tested
Antidepressants in TST
Effect of Combined Administration of DMPX and Imipramine
in TST DMPX (3 mg/kg) and imipramine (15 mg/kg), admin-
istered alone, did not affect immobility in the TST (p > 0.05)
in mice. However, when given together, the duration of mouse
immobility was significantly shortened (p < 0.001) (Fig. 2b).
Two-way ANOVA indicated a significant effect of imipra-
mine (F(1,32) = 15.54, p = 0.0004), a significant effect of
DMPX (F(1,32) = 36.92, p < 0.0001), and a significant
interaction between imipramine and DMPX (F(1,32) = 9.736,
p = 0.0038).
Effect of Combined Administration of DMPX and Escitalopram
in TST DMPX (3 mg/kg) and escitalopram (2 mg/kg), admin-
istered alone, did not affect immobility in the TST (p > 0.05)
in mice. However, when given together, the duration of mouse
immobility was significantly shortened (p < 0.001) (Fig. 2b).
Two-way ANOVA showed no effect of escitalopram
(F(1,33) = 0.5905, p = 0.4477), a significant effect of
DMPX (F(1,33) = 31.61, p < 0.0001), and a significant in-
teraction between escitalopram and DMPX (F(1,33) =
6.251, p = 0.0176).
Effect of Combined Administration of DMPX and Reboxetine
in TST DMPX (3 mg/kg) and reboxetine (2.5 mg/kg), admin-
istered alone, did not affect immobility in the TST (p > 0.05)
in mice. However, when given together, the duration of mouse
immobility was significantly shortened (p < 0.001) (Fig. 2b).
Two-way ANOVA showed a significant effect of
reboxetine (F(1,34) = 6.851, p = 0.0131), a significant effect
of DMPX (F(1,34) = 21.82, p < 0.0001), and no interaction
between reboxetine and DMPX (F(1,34) = 3.640, p = 0.0649).
Fig. 2 Effect of combined administration of DMPX and antidepressants
in the FST (a) and TST (b) in mice. Antidepressants and saline were
administered i.p. 60 min, whereas DMPX i.p. 30 min before the test.
Each experimental group consisted of 10 animals. The data are
presented as the means ± SEM. ***p < 0.001, ****p < 0.0001 versus
respective antidepressant-treated group; ^^p < 0.01, ^^^^p < 0.0001 ver-
sus DMPX-treated group (two-way ANOVA followed by Bonferroni’s
post hoc test)
Fig. 1 The antidepressant-like activity of DMPX in the FST (a) and TST
(b) in mice. DMPX and saline were administered i.p. 30 min before the
test. Each experimental group consisted of 10 animals. The data are pre-
sented as the means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 versus
control group (one-way ANOVA followed by Dunnett’s post hoc test)
Neurotox Res (2019) 35:344–352 347
Spontaneous Locomotor Activity
Effect of DMPX on Locomotor Activity in Mice The effect of
DMPX (3, 6, and 12 mg/kg) on the spontaneous locomotor
activity in mice is shown in Table 1. Statistical analysis of the
results demonstrated that DMPX at doses of 3, 6, and
12 mg/kg had no statistically significant effects on animal’s
locomotor activity versus the control group (one-way
ANOVA: F(3,28) = 1.467, p > 0.05).
Effect of Combined Administration of DMPX and Tested
Drugs on Locomotor Activity in Mice
The effect of combined administration of DMPX and the an-
tidepressants on locomotor activity is shown in Table 2.
DMPX, imipramine, escitalopram, and reboxetine given alone
or in combination had no statistically significant effects on
mice locomotor activity.
Two-way ANOVA demonstrated:
(A): no effect of imipramine (F(1,26) = 3.396, p = 0.0768),
a significant effect of DMPX (F(1,26) = 5.144, p =
0.0319), and no interaction (F(1,26) = 0.5452, p = 0.4669).
(B): no effect of escitalopram (F(1,26) = 0.2310, p= 0.6348),
a significant effect of DMPX (F(1,26) = 6.356, p= 0.0182),
and no interaction (F(1,26) = 0.003379, p= 0.9541).
(C): no effect of reboxetine (F(1,26) = 0.08845, p =
0.3556), no effect of DMPX (F(1,26) = 3.523, p =
0.0718), and no interaction (F(1,26) = 0.4887, p = 0.4907).
Pharmacokinetic Studies
Pharmacokinetic studies outcomes are shown in Table 3.
In the case of combined administration of DMPX with
imipramine, no significant changes in drugs concentration
were observed in murine serum and brain homogenates.
DMPX increased the concentrations of escitalopram and
reboxetine (t test: p < 0.05) in serum without significant
changes in brain tissue.
Discussion
Adenosine system’s capability to regulate a large number of
physiological processes including the CNS activity is well-
documented (Jenner 2003; Jenner et al. 2009; Perez-Lloret
and Merello 2014). The amount of adenosine determines
whether adenosine suppresses or intensifies neurotransmis-
sion in the CNS. Under physiological conditions, adenosine
levels in the brain are maintained at 25–250 nM. The A1Rs
and A2ARs are the main subtypes involved in the regulation of
mental disorders, including anxiety or depression (Ruby et al.
2011). A1Rs and A2ARs have a greater binding affinity for
adenosine than the A2BR and A3R (10–100 nM, 1–5 mM,
respectively) (Fredholm et al. 1999, 2005a, b; Fredholm
2010; Ruby et al. 2011). The highest density of A1Rs is found
in neurons of cortex, hippocampus, cerebellum, as well as in
dorsal horn of spinal cord (Mahan et al. 1991; Dixon et al.
1996; Fredholm et al. 2000). These receptors participate in the
tonic inhibition of neuronal activity. Presynaptic A1Rs regu-
late the release of neurotransmitters, whereas postsynaptic
A1Rs modulate the activity of K
+ channels (Ebersolt et al.
1983; Linden 1991; Linden et al. 1991; Heurteaux et al.
1995). Adenosine A2ARs are expressed mainly in the dorsal
and ventral striatum and olfactory tubercle (Schiffmann et al.
1991a, b; Fink et al. 1992; Svenningsson et al. 1997a, b; Rosin
et al. 1998). They exert a stimulating effect on neurons, in-
creasing the level of cAMP in the CNS. It is also known that
A2ARs bind to other neurotransmitter receptors, including do-
pamine (mainly D2) and glutamate receptors. Such receptor-
receptor interaction seems to be necessary for striatal function
and may be impaired in mental diseases (Ferré et al. 1992,
1996a, b, 1997; Ferré and Fuxe 1992). A growing evidence
supports their influence on behavior, mood, and cognitive
function, which results from a close relationship between the
adenosine modulation and the dopaminergic and glutamater-
gic transduction (Fredholm et al. 2005a).
Table 2 Effect of treatments on spontaneous locomotor activity in mice
Treatment (mg/kg) Distance traveled (cm)
Saline + saline (control group) 640.7 ± 74.67
DMPX 3 + saline 955.8 ± 121.8
Imipramine 15 + saline 524.8 ± 96.23
DMPX 3 + imipramine 15 685.2 ± 102.9
Escitalopram 2 + saline 706.5 ± 110.8
DMPX 3 + escitalopram 2 1007 ± 145.2
Reboxetine 2.5 + saline 611.1 ± 163.9
DMPX 3 + reboxetine 2.5 755.2 ± 81.50
Antidepressants and saline were administered i.p. 60 min, whereas
DMPX i.p. 30 min before the test. Distance traveled was recorded be-
tween the second and the sixth min of the test. Each experimental group
consisted of eight animals. Data are presented as the means ± SEM (two-
way ANOVA followed by Bonferroni’s post hoc test)
Table 1 Effect of DMPX on spontaneous locomotor activity in mice
Treatment (mg/kg) Distance traveled (cm)
Saline (control group) 525.1 ± 79.04
DMPX 3 754.0 ± 72.81
DMPX 6 690.8 ± 62.92
DMPX 12 687.1 ± 102.5
DMPX and saline were administered i.p. 30 min before the test. Distance
traveled was recorded between the second and the sixth min of the test.
Each experimental group consisted of eight animals. The data are presented
as the means ± SEM. The results were considered statistically significant if
p < 0.05 (one-way ANOVA followed by Dunnett’s post hoc test)
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It was found that both adenosine and its analogs (e.g., 2-
chloroadenosine) increased the immobility time in the FST,
which equates to behavioral despair (Duman 2010). On the
contrary, the non-selective inhibition of ARs in the CNS seems
to induce antidepressant-like behavior in animals. One of the
tested non-selective AR antagonist was caffeine, which in a
dose-dependent manner effectively prolonged a mobility period
in the FST (El Yacoubi et al. 2003; Szopa et al. 2016). Research
aimed at determining whether selective genetic or pharmacolog-
ical inhibition of A2ARswill contribute to the antidepressant-like
effect has been carried out recently (El Yacoubi et al. 2001,
2003; Yamada et al. 2013). The suppression of the behavioral
despair was observed by El Yacoubi et al. (2001) in mice with
the genetically inactive A2ARs. In turn, Coelho et al. (2014)
demonstrated that the rodents overexpressing A2ARs in the
CNS structures, such as cortex, striatum, and hippocampus, ex-
hibit symptoms of depression. The period of immobility in the
FSTand TSTwas shortened, inter alia, by the acute oral admin-
istration of istradefylline (Yamada et al. 2013) and i.p. injection
of single dose of ZM241385 or SCH58261 (El Yacoubi et al.
2001, 2003). Here, the dose-dependent antidepressant-like ef-
fect, in both the FSTand TST, has been demonstrated for anoth-
er A2AR antagonist, i.e., DMPX, which displays higher selec-
tivity for A2A receptors over A1 receptors. Of the three tested
doses (3, 6, and 12 mg/kg), only the lowest dose did not change
the mice behavior. Also, subchronic and chronic administration
of a selective antagonist of A2AR, istradefylline, is characterized
by a dose-dependent effect in the FST (studied dose range 0.16–
2.5 mg/kg, per os) (Yamada et al. 2013) and the learned help-
lessness test (LH) in the rat (studied dose range 0.31–5.0 mg/kg,
per os) (Yamada et al. 2014).
However, there is lack of information about the interaction
between A2AR antagonists and therapeutic agents commonly
used in the treatment of patients with depression. Monoamine
hypothesis of depression assumes that the essential reason of
depressive symptoms is a diminution of NA, 5-HT, andDA level
in the CNS (Akiskal and McKinney 1973; Delgado 2000).
Therapeutic agents that elevate the levels of these monoamine
transmitters have been shown to be effective in the depressive
disorders (Gillman 2007). The stimulation of the monoaminergic
system, notably noradrenergic and serotonergic, by A2AR block-
ade may also produce a similar antidepressant effect (Yamada
et al. 2014). In our studies, we have demonstrated the synergism
of the antidepressant-like activity of the A2AR antagonist,
DMPX, and selected antidepressants from various therapeutic
groups. DMPX, imipramine, escitalopram, and reboxetine were
injected at doses that did not affect the animals’ behavior in the
FST, TST, and locomotor activity test. Concomitant administra-
tion of DMPX with these agents resulted in a significant stimu-
lation of mice motility either in the FSTor TST. The reliability of
the obtained data is supported by the fact that observed effects
did not correspond with increase in the mice spontaneous loco-
motor activity. This means that observed antidepressant-like ac-
tivity of the studied agents is not a false positive.
It has been previously demonstrated that non-selective AR
antagonist, caffeine, at a non-effective dose (5 mg/kg) potenti-
ated the activity of antidepressants belonging to different classes
(i.e., fluoxetine, paroxetine, escitalopram, imipramine, desipra-
mine, reboxetine, venlafaxine, moclobemide, mianserin,
milnacipran, bupropion, and agomelatine) (Kale and Addepalli
2014; Poleszak et al. 2015, 2016b; Szopa et al. 2016, 2017). The
antidepressant-like effect of the analyzed drug-drug combina-
tions (DMPX-imipramine, DMPX-escitalopram, and DMPX-
reboxetine) observed in our study is probably the result of the
sum of their action on the monoaminergic transmission.
Moreover, it is well-known that stress-induced illnesses, such
as depression, are closely related to the hypothalamic-pituitary-
adrenal axis (HPA) (Pariante and Miller 2001; Pariante and
Lightman 2008). For example, maternal separation, which is a
model of depression (Vetulani 2013), was shown to increase
corticosterone plasma levels (Biagini et al. 1998). The modifi-
cation of this hormonal system activity plays an essential role in
the action of TCAs and SSRIs (Reul et al. 1993, 1994). The
release of steroid stress hormone, e.g., cortisol, corticosterone, is
controlled by the adenosinergic system (Scaccianoce et al. 1989;
Chau et al. 1999). Yamada et al. (2013) showed that injection of
corticosterone suppressed the antidepressant-like behavior ob-
served in rats after administration of A2AR antagonists.
Table 3 Effect of DMPX on the concentration of antidepressants in mouse serum and brain
Treatment
(mg/kg)
Antidepressant concentration in serum (ng/ml) Antidepressant concentration in brain (ng/g)
Imipramine 15 + saline (metabolite-desipramine)
Imipramine 15 + DMPX 3 (metabolite-desipramine)
229.5 ± 31.92
(39.20 ± 4.72)
215.0 ± 38.64
(40.66 ± 8.23)
p = 0.7767
p = 0.8826
6193 ± 466.5
(299.0 ± 42.22)
7166 ± 1523
(183.0 ± 39.19)
p = 0.5490
p = 0.3968
Escitalopram 2 + saline
Escitalopram 2 +DMPX 3
54.87 ± 3.76
77.55 ± 6.72 *
p = 0.0109 639.1 ± 69.29
780.5 ± 103.9
p = 0.2721
Reboxetine 2.5 + saline
Reboxetine 2.5 + DMPX 3
91.90 ± 7.60
126.3 ± 11.70 *
p = 0.0278 226.7 ± 30.82
159.0 ± 11.59
p = 0.0546
Antidepressants were administered i.p. 60 min, whereas DMPX i.p. 30 min before decapitation. Each experimental group consisted of 10 animals.
Results are presented as mean values ± SEM. *p < 0.05 versus the respective control group (Student’s t test)
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Accordingly, A2AR antagonists through direct and/or indirect
modulation of the HPA axis can influence stress-induced dis-
eases (Yamada et al. 2014). Therefore, the effects on the HPA
axis may be another underpinning of the behavioral effects fol-
lowing concomitant administration of DMPX and antidepres-
sants. Because antidepressants were shown to produce different
effects on the HPA axis (depending on the primary mechanism
of action/acute or chronic administration), it may be hypothe-
sized that adding adenosine-mediated impact on the stress axis
to the effects of antidepressant drugs on this axis, may be ben-
eficial in terms of depression treatment.
Because DMPX is a caffeine analog, it is probable that its
pharmacokinetics is similar to that of other xanthines. DMPX
exhibits 100% bioavailability after both i.p. and per os admin-
istration (Yang et al. 2007). The main xanthine-metabolizing
isoenzyme is CYP1A2. This isoenzyme is also engaged in the
biotransformation of most drugs, including psychotropics
(Caccia 1998; Nelson et al. 2004; Guengerich 2008; Zanger
et al. 2008). Therefore, there was a high expectation of an
interaction between DMPX and antidepressants: imipramine,
escitalopram, and reboxetine. There is no information on the
metabolism of DMPX either in rodents or in humans. Based on
the data collected during the HPLC analysis, we found that
DMPX does not significantly affect the level of imipramine,
as well as desipramine (an active metabolite of imipramine) in
mice. Similarly, in our previous studies, in which caffeine was
used in the same scheme, there were no changes in serum
concentration of imipramine (Szopa et al. 2016). The combined
use of caffeine and reboxetine or escitalopram also did not
contribute to the altered levels of these antidepressants in serum
of mice (Szopa et al. 2016). Notwithstanding, in the case of a
concomitant administration of DMPX with reboxetine and
escitalopram, a small, but statistically significant enhancement
in their concentrations in serum was found. Escitalopram and
reboxetine levels in brain tissue did not increase/decrease sta-
tistically when administered with DMPX. It is astounding that
the changes in levels of escitalopram/reboxetine in murine se-
rum did not reflect the changes in their levels in brain homog-
enates. The reason for this may be a delay in the transport of
these drugs across the blood-brain barrier (Burke and Preskorn
2004). The source of DMPX-escitalopram and DMPX-
reboxetine interactions shown in our study is not entirely clear.
The results imply that the interaction betweenDMPX and imip-
ramine probably takes place in the pharmacodynamic phase,
i.e., at the neurotransmitter or receptor level, etc.
Conclusions
Based on our and quoted in this paper outcomes, it can be
inferred that the adenosine system plays a role in several animal
tests for depression and the selective inhibitors of A2AR reverse
this behavior. The present study supports the possibility of
augmenting the antidepressant pharmacotherapy with DMPX
or different A2AR antagonists. The interaction between the test-
ed xanthine analog and imipramine seems to be exclusively
pharmacodynamic in nature, whereas an increased antidepres-
sant activity of escitalopram/reboxetine was at least partly re-
lated to its pharmacokinetic interaction with DMPX. In sum-
mary, the presented results indicate that A2AR may be a useful
target for the therapy of depressive disorders. A2AR antagonist
can be an advantageous complement to the current antidepres-
sant pharmacotherapy, but it is necessary to perform further
studies, which shall explore this issue.
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